Selected results flowing from IFFIm funding

• Delivering on improved prices
  IFFIm funding has allowed GAVI to make a three-year binding commitment to purchase vaccine at a reduced price by making a longer-term commitment. As a result of this funding, the reduction in price of the pentavalent vaccine (i.e., a single injection that includes vaccination against diphtheria, pertussis and tetanus, Haemophilus influenzae type b and hepatitis B) is 7.7%. Additionally, the availability of IFFIm funding over the next decade is supporting security of supply by giving assurance of GAVI support for the pentavalent vaccine in the future. This is an incentive to new manufacturers to enter the market in the coming years to further reduce the price.
• Lives saved
  By the end of 2007, through IFFIm, an estimated 3.8 million additional children will have been reached with vaccine against Hib, 14.5 million with vaccine against Hepatitis B, and 4.4 million children with vaccine against yellow fever.
• Maternal and neonatal tetanus
  38 million women of child-bearing age will be targeted for immunisation in 19 countries, saving between 204,000 and 314,000 lives.
• Measles
  IFFIm funds will have contributed importantly to a reduction in the number of global measles deaths from 480,000 in 2003 to an estimated 170,000 in 2010. By the end of 2007, $139 million of IFFIm money and pledges will have given a critical boost to the work of the Measles Initiative. In 2007, nearly 240 million children will have been immunised against measles in supplementary campaigns.
  
  Measles vaccination campaigns are also contributing to the reduction of child deaths from other causes. They have become a channel for the delivery of other life-saving interventions, such as bed nets to protect against malaria, de-worming medicine and vitamin A supplements.

For more information see http://www.measlesinitiative.org/press/GAVI22Feb2007.pdf